Hepatocellular Carcinoma in Asia: Physician and Patient Perspectives on Surveillance, Diagnosis, and Treatment

dc.contributor.authorMohamed R.
dc.contributor.authorWang W.
dc.contributor.authorTanwandee T.
dc.contributor.authorHasan I.
dc.contributor.authorPham C.P.
dc.contributor.authorLim Y.S.
dc.contributor.authorLu S.N.
dc.contributor.authorMunisamy M.
dc.contributor.authorTran T.T.H.
dc.contributor.authorRatnawati E.
dc.contributor.authorSukeepaisarnjaroen W.
dc.contributor.authorKarababa M.
dc.contributor.authorTan C.K.
dc.contributor.correspondenceMohamed R.
dc.contributor.otherMahidol University
dc.date.accessioned2024-07-20T18:30:46Z
dc.date.available2024-07-20T18:30:46Z
dc.date.issued2024-01-01
dc.description.abstractPurpose: In several Asian countries, hepatocellular carcinoma (HCC) is a leading cause of cancer deaths. HCC risk factors in Asia differ from those elsewhere and are changing with the treatment landscape as systemic treatment options increase. This study was conducted to gain insight from physicians and patients into HCC screening, diagnosis, and treatment strategies in Indonesia, Korea, Malaysia, Singapore, Taiwan, Thailand, and Vietnam. Methods: Two cross-sectional, anonymized, online surveys were completed between July and December 2022 by physicians diagnosing and treating HCC (55 questions on risk factors, surveillance, diagnosis, and treatment) and patients ≥ 18 years old diagnosed with HCC (36 questions on disease knowledge, quality of life, and experiences of diagnosis and treatment). Results: Responses were received from 276 physicians in all 7 countries and 130 patients in Thailand, Taiwan, and Vietnam. From the physician’s perspective, surveillance programs are widespread but identify insufficient HCC cases; only 18% are early-stage HCC at diagnosis. From the patient’s perspective, knowledge of risk factors increases after diagnosis, but few seek support from patient associations; patients would benefit from better communication from their doctors. Treatment affordability and side effects are key issues for patients. Conclusions: Awareness of the risk factors for HCC should be raised in primary care and the general population, and surveillance should identify early-stage HCC. Because patients rely on their doctors for support, doctors should better understand their patients’ needs, and patients could be supported by trained nurses or case managers. Programs are needed to increase patients’ access to proven HCC treatments.
dc.identifier.citationJournal of Gastrointestinal Cancer (2024)
dc.identifier.doi10.1007/s12029-024-01089-5
dc.identifier.eissn19416636
dc.identifier.issn19416628
dc.identifier.scopus2-s2.0-85198336526
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/99745
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleHepatocellular Carcinoma in Asia: Physician and Patient Perspectives on Surveillance, Diagnosis, and Treatment
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85198336526&origin=inward
oaire.citation.titleJournal of Gastrointestinal Cancer
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationSunway University
oairecerif.author.affiliationHanoi Medical University
oairecerif.author.affiliationUniversitas Indonesia
oairecerif.author.affiliationAsan Medical Center
oairecerif.author.affiliationChang Gung Memorial Hospital
oairecerif.author.affiliationUniversiti Malaya
oairecerif.author.affiliationSrinagarind Hospital
oairecerif.author.affiliationSingapore General Hospital
oairecerif.author.affiliationCOR2ED
oairecerif.author.affiliationIndonesian Cancer Information and Support Center (CISC)
oairecerif.author.affiliationLiver Disease Prevention and Treatment Research Foundation

Files

Collections